|
Name |
Callitrin
|
| Molecular Formula | C15H22O2 | |
| IUPAC Name* |
(3R,3aR,5R,6R,7aR)-6-ethenyl-3,6-dimethyl-5-prop-1-en-2-yl-3,3a,4,5,7,7a-hexahydro-1-benzofuran-2-one
|
|
| SMILES |
C[C@@H]1[C@H]2C[C@@H]([C@@](C[C@H]2OC1=O)(C)C=C)C(=C)C
|
|
| InChI |
InChI=1S/C15H22O2/c1-6-15(5)8-13-11(7-12(15)9(2)3)10(4)14(16)17-13/h6,10-13H,1-2,7-8H2,3-5H3/t10-,11-,12-,13-,15+/m1/s1
|
|
| InChIKey |
HHMGIPSZHRMYCD-HVNMYJMUSA-N
|
|
| Synonyms |
Callitrin; (3R,3aR,5R,6R,7aR)-3,6-Dimethyl-5-(prop-1-en-2-yl)-6-vinylhexahydrobenzofuran-2(3H)-one; 2(3H)-Benzofuranone, 6-ethenylhexahydro-3,6-dimethyl-5-(1-methylethenyl)-, (3R,3aR,5R,6R,7aR)-; 2(3H)-Benzofuranone, 6-ethenylhexahydro-3,6-dimethyl-5-(1-methylethenyl)-, [3R-(3.alpha.,3a.alpha.,5.alpha.,6.beta.,7a.alpha.)]-; 66964-63-4
|
|
| CAS | NA | |
| PubChem CID | 14038380 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 234.33 | ALogp: | 4.2 |
| HBD: | 0 | HBA: | 2 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 26.3 | Aromatic Rings: | 2 |
| Heavy Atoms: | 17 | QED Weighted: | 0.531 |
| Caco-2 Permeability: | -4.613 | MDCK Permeability: | 0.00002990 |
| Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.01 |
| 30% Bioavailability (F30%): | 0.006 |
| Blood-Brain-Barrier Penetration (BBB): | 0.119 | Plasma Protein Binding (PPB): | 80.08% |
| Volume Distribution (VD): | 1.631 | Fu: | 25.17% |
| CYP1A2-inhibitor: | 0.144 | CYP1A2-substrate: | 0.278 |
| CYP2C19-inhibitor: | 0.126 | CYP2C19-substrate: | 0.865 |
| CYP2C9-inhibitor: | 0.082 | CYP2C9-substrate: | 0.402 |
| CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.495 |
| CYP3A4-inhibitor: | 0.859 | CYP3A4-substrate: | 0.462 |
| Clearance (CL): | 2.773 | Half-life (T1/2): | 0.228 |
| hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.437 |
| Drug-inuced Liver Injury (DILI): | 0.447 | AMES Toxicity: | 0.007 |
| Rat Oral Acute Toxicity: | 0.057 | Maximum Recommended Daily Dose: | 0.147 |
| Skin Sensitization: | 0.408 | Carcinogencity: | 0.114 |
| Eye Corrosion: | 0.567 | Eye Irritation: | 0.895 |
| Respiratory Toxicity: | 0.828 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001925 | ![]() |
0.400 | D0K7LU | ![]() |
0.288 | ||
| ENC001895 | ![]() |
0.400 | D0S3WH | ![]() |
0.247 | ||
| ENC003248 | ![]() |
0.353 | D04SFH | ![]() |
0.228 | ||
| ENC003099 | ![]() |
0.338 | D0G6AB | ![]() |
0.216 | ||
| ENC003670 | ![]() |
0.328 | D0I2SD | ![]() |
0.202 | ||
| ENC003551 | ![]() |
0.324 | D03UQM | ![]() |
0.200 | ||
| ENC003753 | ![]() |
0.321 | D07BSQ | ![]() |
0.198 | ||
| ENC002226 | ![]() |
0.313 | D0P0HT | ![]() |
0.194 | ||
| ENC000782 | ![]() |
0.313 | D0D2TN | ![]() |
0.192 | ||
| ENC003480 | ![]() |
0.311 | D08PIQ | ![]() |
0.192 | ||